The future of
single-domain antibodies



News-Events

Meet us at Writing and Editing the Ubiquitine Code

Bilbao, Spain - 26-27 February

Meet us at the Writing and Editing the Ubiquitine Code conference in Bilbao, Spain from February 26th to 27th, 2019.

This international meeting will gather experts and scientists from all over the world to discuss the latest advances regarding Post-translational modifications (PTM) by members of the ubiquitin family.

Dr. Jean-Christophe Rain, CSO, will attend this event. He will be happy to meet you and present our antibodies tools to study the ubiquitin modifications.

Feel free to Contact us to arrange a meeting with him to discuss your project.

Congratulations for your publication!

Barcelona, Spain - 13 Feb

Congratulations to Raul Estevez Povedano and his team for their paper  «Structural basis for the dominant or recessive character of GLIALCAM mutations found in leukodystrophies» in Hum Mol Genet. We are very happy to see that the VHH against GLIALCAM were useful for their research.

We are looking forward handling new projects with our customers.

If you are interested in generating or optimizing your own single domain antibodies fell free to contact us to know more about our hybribody services.

Meet us at LS2 meeting – Cells, Molecules and Organisms

Zurich, Switzerland - 13-14 Feb

Meet us at the LS2 meeting – Cells, Molecules and Organisms in Zurich, Switzerland from February 13th to 14th , 2020.

This conference will bring together scientists from all nations and backgrounds to explore the large spectrum united under the umbrella of Life Sciences

Söhnke Kühnhold Business Development Manager will attend this event. He will be happy to meet you and present our services, ULTImate Y2H, ULTImate YChemH, Hybribody.

Feel free to contact us to arrange a meeting with our team!

Hybrigenics Services is fully independent from Hybrigenics Pharma

Evry, France - october 2019

Please note that Hybrigenics Services (www.hybrigenics-services.com) and Hybrigenics Pharma (www.hybrigenics.com) have been two financially independent companies since January 2017 despite keeping similar names. Our activities are completely distinct and our operations entirely separate.

Hybrigenics Pharma announced on October 23, 2018 that the clinical development of its only drug candidate was discontinued for lack of efficacy. The winding-up of the company was suspended in January, 2019 when Hybrigenics Pharma received a takeover offer. On October 15, 2019 Hybrigenics Pharma announced its takeover by DMS Group with immediate effect.

None of this affects Hybrigenics Services in any way, nor the research we conduct for our clients and partners. We regret the confusion this might cause.

We thank investigators and companies across the world for their trust and continued interest in our services.

 

Old news

Back to Top